Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Golden Jubilee National Hospital |
---|---|
Information provided by: | Golden Jubilee National Hospital |
ClinicalTrials.gov Identifier: | NCT00378872 |
We will compare the effectiveness of Quixil and Tranexamic acid in reducing bleeding during hip and knee joint replacements.
Condition | Intervention |
---|---|
Arthroplasty, Replacement, Hip Arthroplasty, Replacement, Knee Hemorrhage |
Drug: IV Tranexamic acid 10mg/kg pt body weight Drug: Quixil topical sealant |
Study Type: | Interventional |
Study Design: | Active Control, Parallel Assignment, Prevention, Randomized, Safety/Efficacy Study, Single Blind |
Official Title: | Prospective Randomised Trial Comparing Intraoperative Topical Quixil and Intravenous Tranexamic Acid, in Reduction of Blood Loss Following Primary Hip
|
Enrollment: | 132 |
Study Start Date: | June 2006 |
Study Completion Date: | May 2008 |
Primary Completion Date: | May 2008 (Final data collection date for primary outcome measure) |
This is a prospective randomised controlled trial to compare the benefits of Quixil vs. Tranexamic acid in reducing blood loss.
Both medicines are used for the reduction of blood loss in major joint surgery; previous studies have shown each one to be effective and safe, but they have not been directly compared in this setting.
We will compare the blood loss in each of 3 groups: tranexamic acid used, Quixil used, and control group (neither drug used). Blood loss is to be calculated from height, body weight and difference between pre and post-operation haematocrit.
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United Kingdom, Scotland | |
Golden Jubilee National Hospital | |
Clydebank, Scotland, United Kingdom, G81 4HX |
Principal Investigator: | Jamie S McConnell, MB BCh MRCS | Golden Jubilee National Hospital, NHS Scotland |
Responsible Party: | Golden Jubilee National Hospital ( Mr Andrew Kinninmonth ) |
Study ID Numbers: | GJNH-06-01, Eudract number 2006-001299-19 |
Study First Received: | September 20, 2006 |
Last Updated: | May 13, 2008 |
ClinicalTrials.gov Identifier: | NCT00378872 History of Changes |
Health Authority: | United Kingdom: Medicines and Healthcare Products Regulatory Agency |
Fibrin Modulating Agents Antiplasmin Antifibrinolytic Agents |
Tranexamic Acid Hemorrhage Hemostatics |
Fibrin Modulating Agents Antifibrinolytic Agents Pathologic Processes Coagulants Molecular Mechanisms of Pharmacological Action Therapeutic Uses |
Hematologic Agents Tranexamic Acid Hemorrhage Hemostatics Pharmacologic Actions |